Shenghui Tang

30PUBLICATIONS
174CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapyMolecular targetsMedical biotechnology not elsewhere classifiedPharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (30)

|Mar 06, 2026
FDA Approval Summary: Pembrolizumab for the Treatment of HER2-Positive Gastric Cancer.

Sandra J Casak, Yiming Zhang, Chi Song

|Jan 26, 2026
FDA Approval Summary: Tarlatamab for the Treatment of Extensive-Stage Small Cell Lung Cancer.

Yufan Liu, Jeannette Nashed, Amy K Barone

|Sep 05, 2025
FDA Approval Summary: Vorasidenib for IDH-Mutant Grade 2 Astrocytoma or Oligodendroglioma Following Surgery.

Michael I Barbato, Amy K Barone, Stephanie L Aungst

|Aug 27, 2025
FDA Approval Summary: Datopotamab Deruxtecan-dlnk for Treatment of Patients with Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer.

Melanie Royce, Mirat Shah, Lijun Zhang

|Aug 22, 2025
US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, <i>PIK3CA</i>-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Locally Advanced or Metastatic Breast Cancer.

Suparna Wedam, Preeti Narayan, Haley Gittleman

|Aug 18, 2025
FDA Approval Summary: Nogapendekin Alfa Inbakicept-pmln with BCG for BCG-Unresponsive Carcinoma In Situ.

Brian L Heiss, Elaine Chang, Hee-Koung Joeng

Pageof 5

Frequent Collaborators

28 joint publications

Richard Pazdur

22 joint publications

Laleh Amiri-Kordestani

15 joint publications

William Pierce

12 joint publications

Paul G Kluetz